Szymonowicz Klaudia, Oeck Sebastian, Malewicz Nathalie M, Jendrossek Verena
Institute of Cell Biology (Cancer Research), University of Duisburg-Essen Medical School, 45122 Essen, Germany.
Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06520, USA.
Cancers (Basel). 2018 Mar 18;10(3):78. doi: 10.3390/cancers10030078.
Genetic alterations driving aberrant activation of the survival kinase Protein Kinase B (Akt) are observed with high frequency during malignant transformation and cancer progression. Oncogenic gene mutations coding for the upstream regulators or Akt, e.g., growth factor receptors, RAS and phosphatidylinositol-3-kinase (PI3K), or for one of the three Akt isoforms as well as loss of the tumor suppressor Phosphatase and Tensin Homolog on Chromosome Ten (PTEN) lead to constitutive activation of Akt. By activating Akt, these genetic alterations not only promote growth, proliferation and malignant behavior of cancer cells by phosphorylation of various downstream signaling molecules and signaling nodes but can also contribute to chemo- and radioresistance in many types of tumors. Here we review current knowledge on the mechanisms dictating Akt's activation and target selection including the involvement of miRNAs and with focus on compartmentalization of the signaling network. Moreover, we discuss recent advances in the cross-talk with DNA damage response highlighting nuclear Akt target proteins with potential involvement in the regulation of DNA double strand break repair.
在恶性转化和癌症进展过程中,经常观察到驱动存活激酶蛋白激酶B(Akt)异常激活的基因改变。编码Akt上游调节因子(如生长因子受体、RAS和磷脂酰肌醇-3-激酶(PI3K))或三种Akt亚型之一的致癌基因突变,以及肿瘤抑制因子第10号染色体上的磷酸酶和张力蛋白同源物(PTEN)的缺失,都会导致Akt的组成性激活。通过激活Akt,这些基因改变不仅通过磷酸化各种下游信号分子和信号节点促进癌细胞的生长、增殖和恶性行为,还可能导致多种类型肿瘤的化疗和放疗抗性。在此,我们综述了目前关于决定Akt激活和靶点选择机制的知识,包括微小RNA的参与,并重点关注信号网络的区室化。此外,我们讨论了与DNA损伤反应相互作用的最新进展,强调了可能参与DNA双链断裂修复调控的核Akt靶蛋白。